techkenyot.com
techkenyot.com July 15, 2018


Sage Therapeutics Reports Successful Depression Drug Study

08 December 2017, 10:22 | Henrietta Morgan

SAGE Therapeutics Inc

SAGE Therapeutics Inc

Sage Therapeutics shares are once again rocketing up this morning, this time based on positive results from a small Phase II study of an oral version of their depression therapy. (NASDAQ:SAGE). Denver Advisors Ltd Liability Com has invested 0.02% of its portfolio in Sage Therapeutics, Inc. Dupont Cap accumulated 13,528 shares.

Long one of the most volatile stocks in biotech, Sage says that SAGE-217 clearly hit the goal post for statistical significance in major depressive disorder, achieving a 64% success rate in achieving clinical remission on a commonly used score for depression against 23% on a placebo.

Trading stocks at an all time highs is usually a winning strategy. State of Wisconsin Investment Board acquired a new position in Sage Therapeutics during the second quarter valued at approximately $1,991,000.

Lookout the Analyst's Suggestions:: Merck & Co., Inc. (MRK)
Twelve investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Private Management invested in 263,602 shares. 12,163 were accumulated by Crestwood Advisors Limited Liability Company.

SAGE has been the subject of several other research reports. J P Morgan Chase & Co lowered their price target on shares of Sage Therapeutics from $99.00 to $85.00 and set an "overweight" rating for the company in a research report on Tuesday, September 12th. (NASDAQ:SAGE). Jabre Sa has invested 0.03% of its portfolio in Sage Therapeutics, Inc. ValuEngine upgraded Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, August 28th. About 6.61 million shares traded or 676.95% up from the average. Tightening the gaze, stock performance for the last 5 trading days is -2.39%. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.40. Sage Therapeutics has a 12 month low of $44.55 and a 12 month high of $100.50. Therefore 88% are positive.

In the grander scheme, "While some investors may want to take profits (with stock up 75% before the open), we think the long-range prospects for SAGE are positive and maintain our BUY rating". From the opening price, the stock has seen a change of -0.40% recently clocking in with a price of $160.54. SAGE Therapeutics had 45 analyst reports since September 3, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with "Buy" rating in Thursday, November 9 report. Bank of America maintained the shares of SAGE in report on Thursday, November 16 with "Buy" rating. The firm earned "Buy" rating on Tuesday, September 12 by Leerink Swann. Stifel Nicolaus maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, June 29 with "Outperform" rating. The firm has "Buy" rating given on Tuesday, September 12 by Canaccord Genuity. As per Thursday, December 7, the company rating was maintained by Leerink Swann.

More recent Sage Therapeutics, Inc.

Technical Tracker: Following Shares of UK Index MSCI Ishares (EWU)
This stock has garnered attention of analysts and investors over the past few weeks as the stock has come into mainstream focus. Looking at some moving average levels, the 200-day is at 35.64, the 50-day is 37.38, and the 7-day is sitting at 36.72.

SAGE Therapeutics Inc (NASDAQ:SAGE) is roaring up almost 77% through the market ceiling after a massively successful Phase 2 read-out in major depressive disorder (MDD), earning a new shot of confidence from an already positive bull on the Street.

Praising the depression drug's safety profile, the analyst elaborates: "Safety clean, highly encouraging SAGE-217 showed a clean safety profile with adverse events consistent with prior studies, including headache, dizziness, nausea, and somnolence". (NASDAQ:SAGE) were released by: Schaeffersresearch.com and their article: "SAGE Therapeutics Options Traders Don't Buy Depression Drug Breakout" published on December 07, 2017 as well as Nasdaq.com's news article titled: "Mid-Day Market Update: Duluth Holdings Drops Following Q3 Results; SAGE ..." with publication date: December 07, 2017. Hershey Trust Co. bought a new position in shares of Sage Therapeutics in the 3rd quarter worth about $118,000. The company has market cap of $22.06 million. "There has been little innovation in the discovery and development of treatments for depression in the last two decades", Sage's chief executive, Jeff Jonas, said in a statement.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. It now has negative earnings.

First Warning Forecast: Dropping Temps And Snow
WEATHER BRAINS: You can listen to our weekly 90-minute netcast anytime on the web, or on iTunes . It is important to note that not everyone in the Winter Weather Advisory will see snow.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Other News

Trending Now

Competing Reviews of Woody Allen's Wonder Wheel
Humpty ( Jim Belushi ), Carolina's father and Ginny's husband, struggles with his alcohol abuse and the return of his daughter. It also shows how things in life can change like the seasons but that they also often stay exactly the same.

Sango, PDP chieftain kidnapped
We have no communication with the six occupants of the vehicle including the abductors and no ransom has been made. A family member, Mr Jonathan Mapis, who spoke on the issue, said that the victims were abducted "around 5.30 p.m".

No change in our policy on Palestine, says India
The statement however did not specifically address the issue of Jerusalem as the USA -recognised capital of Israel. PM Modi had skipped Palestine during his visit to Israel in July.

Philippe Coutinho forward admits to Barcelona interest
Coutinho's hat-trick was his first for Liverpool and the Brazilian insists the win over Spartak will live long in his memory. Mundo Deportivo reported on Thursday morning that a deal is already in place for the playmaker to sign a five-year contract.

Paul George, Jerami Grant out vs. Brooklyn Nets in Mexico City
Silver added that the league was exploring the cost involved in a Mexican G League franchise. Last January, the Phoenix Suns played "host" in Mexico, facing the Mavericks and Spurs.

LG to Release Limited Premium Edition of V30 Flagship Smartphone
The smartphone has a 6-inch OLED FullVision display with QHD+ (1440x2880 pixels) resolution. Further, the handset runs Android 8.0 Oreo and comes preloaded with LG Pay integration.

Oscar victor Geoffrey Rush is suing The Daily Telegraph for defamation
Rush's lawyer Nicholas Pullen said police had not been in contact with his client over the allegations. He has previously said that he had not been informed of the existence or nature of any complaint.

Anushka Sharma, family spotted at airport amid speculations of wedding in Italy
Sources told India Today Television that Virat and Anushka are definitely going to take their relationship to the next level. Virat Kohli refers to Anushka Sharma as "Nushki".

THQ Nordic's New Survival Game Enters Early Access Next Week
Fade to Silence promises dynamic, accumulating snow, real-time snow trails, and completely immersive weather effects. Players will assume control of Ash, a "natural but tormented leader" forced to survive a harsh winter.

Marsh & McLennan Companies (MMC) Receiving Somewhat Positive News Coverage, Study Finds
Jefferies downgraded the shares of IP in report on Tuesday, May 3 to "Hold" rating. (NYSE: MMC ) rating on Monday, October 2. Ameriprise Financial Inc. increased its stake in shares of Marsh & McLennan Companies by 2.2% in the first quarter.